首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   10241篇
  免费   852篇
  国内免费   15篇
耳鼻咽喉   111篇
儿科学   345篇
妇产科学   178篇
基础医学   1460篇
口腔科学   192篇
临床医学   1104篇
内科学   1811篇
皮肤病学   112篇
神经病学   848篇
特种医学   323篇
外科学   1180篇
综合类   811篇
一般理论   6篇
预防医学   1058篇
眼科学   165篇
药学   630篇
中国医学   19篇
肿瘤学   755篇
  2023年   80篇
  2022年   79篇
  2021年   178篇
  2020年   134篇
  2019年   173篇
  2018年   223篇
  2017年   143篇
  2016年   190篇
  2015年   199篇
  2014年   247篇
  2013年   379篇
  2012年   488篇
  2011年   532篇
  2010年   301篇
  2009年   271篇
  2008年   483篇
  2007年   620篇
  2006年   580篇
  2005年   509篇
  2004年   453篇
  2003年   394篇
  2002年   394篇
  2001年   307篇
  2000年   313篇
  1999年   232篇
  1998年   143篇
  1997年   79篇
  1996年   74篇
  1995年   67篇
  1994年   71篇
  1993年   79篇
  1992年   160篇
  1991年   155篇
  1990年   154篇
  1989年   163篇
  1988年   156篇
  1987年   194篇
  1986年   144篇
  1985年   144篇
  1984年   129篇
  1983年   105篇
  1981年   64篇
  1980年   62篇
  1979年   79篇
  1978年   75篇
  1976年   65篇
  1974年   72篇
  1973年   80篇
  1972年   65篇
  1971年   66篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Southgate  M. Therese 《JAMA》2006,296(13):1564
  相似文献   
2.
Animal models have traditionally provided the basis for preliminary investigation of new techniques prior to trials taking place in human subjects. The timing of when to proceed with human trials is difficult, as the accuracy of preclinical models can only be determined with hindsight. This review outlines the progression from transplantation in animal models to man. Now that many transplant procedures are well established, it is possible to assess the predictive value and limitations of animal models. These results are of great importance in the current debate about composite tissue allotransplantation (CTA) and in particular facial transplantation. This progression of CTA from animal models to man is outlined and compared with early renal, cardiac, and liver transplants. There is some evidence to suggest that animal models may have been misleading in CTA and that this has effectively delayed the transition to humans. The role for animal models in facial transplantation, which is currently making the step to clinical trials, is discussed.  相似文献   
3.
4.
5.
6.
7.
8.
OBJECTIVE: To characterize dysfunctional labors that lead to cesarean delivery in the second stage and to assess the accuracy of diagnoses of abnormal fetal descent. METHODS: Thirty-one patients delivered by cesarean during the second stage because of abnormal labor or presumed cephalopelvic disproportion were studied and compared to 62 control cesarean cases delivered for the same indications in the first stage. The clinical diagnosis of dysfunctional labor that led to the cesarean was compared to the diagnosis made by retrospective analysis of the labor curves. RESULTS: Cases did not differ from controls delivered in the first stage in maternal age, race, parity, gestational age, weight gain, or the frequency of associated medical complications. The newborns were not significantly different in birth weight,ponderal index, sex, or the incidence of low Apgar scores. Among study patients, 94% had a second stage labor dysfunction determined by graphic labor analysis, predominantly arrest of descent (69%) and failure of descent (28%). In 79% of cases a dysfunctional first stage preceded the abnormal second stage. Among these first stage labor abnormalities, 68% were not recognized during the labor. CONCLUSION: Characteristics of patients delivered by cesarean during the second stage were similar to those delivered before full cervical dilatation. Second stage labor abnormalities were usually preceded by an abnormal first stage. There was considerable inaccuracy in the diagnosis of second stage labor dysfunction.  相似文献   
9.
alpha 1-Antiproteinase is the major inhibitor of proteolytic enzymes, such as elastase, in human plasma. Its elastase-inhibitory capacity can be inactivated by exposure to hydroxyl radicals (.OH) generated either by pulse radiolysis or by an Fe3+-EDTA/H2O2/ascorbic acid system. Inactivation of alpha 1-antiproteinase by radiolytically-generated .OH under anoxic conditions was decreased by adding a range of anti-inflammatory drugs to the reaction mixtures, including the thiol compound penicillamine. However, under conditions favouring formation of oxysulphur radicals, protection by thiols such as penicillamine was much decreased. It is proposed that sulphur-containing radicals resulting from attack of biologically-produced oxidants upon penicillamine in the presence of O2 can themselves inactivate alpha 1-antiproteinase, and that such radicals might contribute to the side-effects produced by penicillamine or gold thiol therapy in rheumatoid arthritis.  相似文献   
10.
Objective Approximately 10% of patients with neurofibromatosis I (NFI) patients will have central nervous system (CNS) tumors. The most common of these are hypothalamic–optic gliomas, followed by brainstem and cerebellar pilocytic astrocytomas. While isolated pilocytic astrocytomas in NFI are well described, the appearance of multiple pilocytic astrocytomas in an individual patient is less common. The most frequent combination in NFI patients with more than one pilocytic astrocytoma is optic tract/hypothalamic and brainstem. Other combinations are exceedingly rare; multiple pilocytic astrocytomas have only been reported once in the cerebral hemispheres in a patient with NFI. This report presents the first documented case, to our knowledge, of multiple pilocytic astrocytomas in the cerebellum of a patient with NF1. Methods Case report. Conclusion The finding of multiple cerebellar pilocytic astrocytomas in a patient with NF1 is important because it expands the spectrum of presentations for patients with NF1 and also highlights specific diagnostic and therapeutic challenges faced by the treating physicians. The genetic and molecular basis of NF1 is reviewed. Strategies of diagnosis and treatment outlined here are relevant to both patients with NF1 and all patients with multiple posterior fossa tumors.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号